~~<i id='2A279EEB2E'><strike id='2A279EEB2E'><tt id='2A279EEB2E'><pre id='2A279EEB2E'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

knowledge

author：leisure time 2025-10-01 17:42:54 - browse：33776

Stoke Therapeutics is still seeking an effective dose for an experimental drug to treat a severe form of childhood epilepsy, following the release of updated data Tuesday that showed disappointing reductions in convulsive seizure activity.

In the latest look at an ongoing mid-stage study, three monthly injections of the Stoke drug, called STK-001, given at a 45-mg dose, resulted in a median 18% reduction in convulsive seizure activity, compared to baseline.

The new analysis was conducted on 16 children diagnosed with a rare form of epilepsy called Dravet syndrome. Last November, in six patients, the drug showed a median 55% reduction in seizure activity.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： AstraZeneca lung cancer study comes in below expectations

knowledge

entertainment

explore

leisure time

knowledge

focus

AkiraSuemori/APAnewasthmatreatmentthatcouldbeadministeredjustonceeverysixmonthshassucceededintwoPhas

WSS

Use doctors trained outside the U.S. to ease the physician shortage

A letter from the executive editor: The 2023 STATUS List

What affirmative action's end means to a medical student

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

Brain technologies pose threats that are all too real, experts warn

hotspot

knowledge

knowledge

How one medical school became remarkably diverse

Dexcom's push to bring CGM to type 2 diabetes patients

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Can gargling with Listerine treat gonorrhea of the mouth?

In age of alternative facts, a scholarly course on calling out crap

AstraZeneca lung cancer study comes in below expectations

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Brain MRIs reveal impact of 'toxic stress' on Black children

Psychedelics group wrestles with new pharma identity

Most antidepressants don't work on kids, teens, study finds

entertainment

GSK’s asthma push continues as drug succeeds in Phase 3 trials

The effects of a landmark ruling on DNA ownership are becoming clearer

STAT wants to know your pick for a great summer read or listen

Is it ever OK for doctors to lie to their patients?

Canadians with cystic fibrosis outlive Americans by a decade

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

explore

leisure time

knowledge

focus